Figure 3.
Prophylactic guanylyl cyclase C (GCC)–specific immunity against colon cancer metastases in liver. BALB/c mice were immunized with control adenovirus (AV) or GCCECD-AV and challenged 1 week later by intrasplenic injection (on day 0) with 1 × 105 CT26-GCCTM mouse colon cancer cells. Mice were killed on day 21, and livers were collected. A) Livers of control- and GCCECD-immunized mice. B) Liver weights of control- and GCCECD-immunized mice. Data shown are means of n = 5 mice per immunization, and error bars indicate upper 95% confidence intervals (P = .088, two-sided Student t test). C) Numbers of liver nodules (n = 11–12 mice per immunization). Bars indicate means (**P = .008, two-sided Welch t test).